REMEGEN (09995): Huang Guobin appointed as independent non-executive director.
Rongchang Biology (09995) announced that Mr. Huang Guobin was appointed as an independent director of the second board of directors at the extraordinary general meeting.
REMEGEN (09995) announced that Mr. Huang Guobin has been appointed as an independent non-executive director of the second board of directors at the temporary shareholders' meeting. Mr. Huang's appointment is effective immediately after the temporary shareholders' meeting and will continue until the end of the second term of the board of directors. Mr. Huang has also been appointed as the chairman of the nomination committee and a member of the strategic committee, effective from his appointment as an independent non-executive director at the temporary shareholders' meeting until the end of the second term of the board of directors.
After the temporary shareholders' meeting, Dr. Ma Lan will no longer serve as an independent non-executive director, chairman of the nomination committee, and member of the strategic committee.
Related Articles
On July 9th, China Alumcan (06898) spent HK$3.85 million to repurchase 5 million shares.
CNSIG Inner Mongolia Chemical Industry (600328.SH): China Salt Alkali Industry obtained the mining rights for natural alkali worth 6.809 billion yuan.
ZHAOKE OPHTH-B(06622): The National Medical Products Administration has accepted the new drug application for NVK002 (0.02% atropine sulfate eye drops) for the treatment of progressive myopia in children.
On July 9th, China Alumcan (06898) spent HK$3.85 million to repurchase 5 million shares.
CNSIG Inner Mongolia Chemical Industry (600328.SH): China Salt Alkali Industry obtained the mining rights for natural alkali worth 6.809 billion yuan.
ZHAOKE OPHTH-B(06622): The National Medical Products Administration has accepted the new drug application for NVK002 (0.02% atropine sulfate eye drops) for the treatment of progressive myopia in children.
RECOMMEND
